- Home
- LGVN
LGVN
Longeveron Inc.
as 06-06-2025 2:38pm EST
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | 23.4M | IPO Year: | 2021 |
| Target Price: | $8.67 | AVG Volume (30 days): | 135.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.77 - $6.40 | Next Earning Date: | 05-08-2025 |
| Revenue: | $2,225,000 | Revenue Growth: | 127.50% |
| Revenue Growth (this year): | -11.58% | Revenue Growth (next year): | 24.82% |
Stock Insider Trading Activity of Longeveron Inc. (LGVN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Soffer Rock | LGVN | Director | May 29 '25 | Sell | $1.28 | 21,000 | $26,750.00 | 220,034 | |
| Soffer Rock | LGVN | Director | May 22 '25 | Sell | $1.32 | 2,000 | $2,640.00 | 220,034 | |
| Hare Joshua | LGVN | Chief Scientific Officer | May 16 '25 | Sell | $1.40 | 5,250 | $7,367.33 | 721,796 |
Latest Longeveron Inc. News
LGVN Breaking Stock News: Dive into LGVN Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
Here's Why Longeveron (NASDAQ:LGVN) Must Use Its Cash Wisely
GlobeNewswire
17 days ago
Longeveron® to Attend BIO International Convention 2025
GlobeNewswire
25 days ago
Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient
Zacks Small Cap Research
a month ago
LGVN Entering Crucial Period in Great Shape
GlobeNewswire
a month ago
Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update
GuruFocus.com
a month ago
Longeveron Inc (LGVN) Q1 2025: Everything You Need To Know Ahead Of Earnings
GlobeNewswire
a month ago
Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
GlobeNewswire
a month ago
Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025
Compare LGVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LGVN Longeveron Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.